Glycogen storage diseases, commonly referred to as GSDs, are sporadic genetic disorders that impact the storage and release of glucose in the body. Although these disorders are not common, they can affect growth, metabolism, and different body functions, especially in infants and pediatric patients.

This guide provides a comprehensive overview of glycogen storage diseases, covering their types, causes, and symptoms, as well as diagnosis and treatment, enabling NEET PG aspirants to develop a clear understanding of these complex conditions. Keep reading to learn more.

What are Glycogen Storage Diseases?

GSDs are numbered systemic disorders, naming the order in which the enzyme defects were described. The age of presentation can range from the neonatal period to adulthood, so patients may not develop symptoms in infancy.

Glycogen storage diseases are a set of rare genetic metabolic disorders that affect the body’s storage or degradation of glycogen, the storage form of glucose. Consumption of carbohydrates produces glucose, which is either used as fuel or stored as glycogen through the process of glycogenesis.

Glycogen is stored primarily in the liver and muscles, and when the body is fasting or exercising, it is converted into glucose through a process called glycogenolysis. Lack of one or more enzymes required for glycogen production or breakdown results in GSDs. Since the body cannot maintain an appropriate blood glucose level, it stores excess glycogen. 

Depending on the organs they affect, GSDs might result in hypoglycemia, hepatomegaly, weakness, and metabolic issues. Although the liver has a higher glycogen concentration, muscles have more glycogen due to their size; hence, changes in either the liver or the muscles cause variances in the presentations of individuals with GSDs.

What are the Types of Glycogen Storage Disease?

The glycogen storage diseases are inherited metabolic disorders, each caused by a particular enzyme deficiency. They can be classified based on the organs involved: liver, skeletal muscle, or both. For each type of disease, a specific set of signs, severity, and clinical outcomes exists.

GSDs primarily affecting the liver include disorders that impair hepatic glucose release, leading to fasting hypoglycemia and hepatomegaly. They are listed in the table below:

Disorder	GSD Type / Enzyme Defect
Glycogen synthase-2 deficiency	GSD type 0a
Glucose-6-phosphatase deficiency	GSD type Ia
Glucose-6-phosphate transporter deficiency	GSD type Ib
Glycogen debrancher enzyme deficiency	GSD type III
Glycogen branching enzyme deficiency	GSD type IV
Liver phosphorylase deficiency	GSD type VI
Phosphorylase kinase deficiency	GSD type IXa
GLUT2 deficiency (Fanconi–Bickel disease)	GSD type XI

These disorders cannot maintain normal glucose homeostasis during fasting. Therefore, dietary therapy is often the cornerstone of treatment.

GSDs primarily affecting skeletal muscle interfere with energy generation during exercise and usually present later in life. They are listed below:

Disorder	GSD Type / Enzyme Defect
Muscle phosphorylase deficiency (McArdle disease)	GSD type V
Phosphofructokinase deficiency	GSD type VII
Phosphoglycerate mutase deficiency	GSD type X
Lactate dehydrogenase A deficiency	GSD type XI
Aldolase A deficiency	GSD type XII
β-enolase deficiency	GSD type XIII
Phosphoglucomutase-1 deficiency	GSD type XIV

These individuals won’t tolerate strenuous exercise because their muscles can’t efficiently access stored glycogen. GSDs affecting both skeletal and cardiac muscle are often more severe and include the following:

Disorder	GSD Type / Enzyme Defect
Lysosomal acid maltase deficiency (Pompe disease)	GSD type IIa
Lysosome-associated membrane protein-2 deficiency	GSD type IIb
Glycogenin-1 deficiency	GSD type XV
Muscle glycogen synthase deficiency	GSD type 0b

1. Glycogen Storage Disease Type I (Von Gierke Disease)

Type I glycogen storage disease (von Gierke disease) is an autosomal recessive disorder caused by defects in the glucose-6-phosphatase system, essential for glucose homeostasis.

Type Ia results from glucose-6-phosphatase deficiency, while type Ib is due to glucose-6-phosphate translocase deficiency and is associated with recurrent infections due to neutrophil dysfunction. Types Ia and Ib are the primary clinically relevant forms.

2. Glycogen Storage Disease Type II-Pompe Disease

GSD type II, also known as Pompe disease or acid maltase deficiency, is a lysosomal storage disorder. It was first described by Pompe in 1932 and differs significantly from other GSDs because glycogen accumulates inside lysosomes rather than the cytoplasm.

The disease is caused by a deficiency of the lysosomal enzyme alpha-1,4-glucosidase, resulting in widespread glycogen accumulation in many tissues. There are 3 clinical forms recognised:

• an infantile-onset form
• a juvenile-onset form
• an adult-onset form

In the classic infantile form, signs such as cardiomyopathy and severe muscle hypotonia dominate the presentation. The juvenile and adult forms mainly cause skeletal muscle impairment; thus, the primary concern becomes progressive muscle weakness.

3. Glycogen Storage Disease Type III (Forbes–Cori Disease)

GSD type III, also known as Forbes–Cori disease or limited dextrinosis, is an autosomal recessive disorder caused by mutations in the AGL gene. This leads to a deficiency of the glycogen debranching enzyme and accumulation of abnormal glycogen, also called limit dextrin.

Here, both the liver and the skeleton are affected. GSD type IIIa, being the most common form, accounts for approximately 85% of the cases, while type IIIb is less common and generally milder.

Clinical features overlap, so it is not always possible to distinguish GSD type III from GSD type I based on physical features.

4. Glycogen Storage Disease Type IV (Andersen Disease)

GSD type IV or Andersen disease (glycogen branching enzyme deficiency) is a rare and serious disorder. Andersen first reported the disease in 1956 in patients with progressive hepatosplenomegaly and with an accumulation of abnormal polysaccharides.

Abnormal glycogen accumulates in tissues due to defective glycogen branching, resulting in liver failure and involvement of the heart and nervous system. The course of the disease is often fulminating, with death occurring early in life; hence, early recognition is essential.

5. Glycogen Storage Disease Type V-McArdle Disease

McArdle disease, or GSD type V, mainly involves skeletal muscle. Muscle glycogen phosphorylase deficiency is the cause of this disease, which was first reported by McArdle in 1951.

Symptoms typically first appear during adolescence or adulthood. Common symptoms include exercise intolerance and muscle fatigue. Due to impaired breakdown of muscle glycogen, the glycolytic pathway is impaired during exercise.

Like other GSDs, McArdle disease is heterogeneous, with symptom severity varying from one individual to another.

6. Glycogen Storage Disease Type VI Hers Disease

GSD type VI, also called Hers disease, is a hepatic glycogenosis and represents a heterogeneous group of disorders. It results from hepatic phosphorylase deficiency or defects in enzymes involved in phosphorylase activation.

Hers first described the disease in 1959. Since the liver is primarily affected, patients usually present with hepatomegaly and mild hypoglycemia. Since the condition has milder symptoms than GSD type I, long-term outcomes are often positive.

7. Glycogen Storage Disease Type VII (Tarui Disease)

GSD type VII, also known as Tarui disease, results from a deficiency of phosphofructokinase (PFK). The enzyme is expressed in skeletal muscle and erythrocytes, and Tarui first reported affected individuals in 1965.

Clinically, GSD type VII is similar to GSD type V, with symptoms mainly centred on exercise intolerance and muscle weakness. Due to impairment at a different step of the glycolytic pathway, there is an inability to generate adequate energy during exercise; thus, the similarity in presentation.

What are the Causes of Glycogen Storage Diseases?

The glycogen storage diseases are inherited due to genetic mutations that affect enzymes responsible for glycogen synthesis, degradation, or transport. This genetic problem makes it impossible for the body to release energy from glycogen, which is inherited in an autosomal recessive trait, but sometimes X-linked.

The causes of GSD are given below:

• Defects in Glycogen Synthesis

Alterations in glycogen synthesis cause certain types of glycogen storage disease. The gene responsible for the primary enzyme for synthesising glycogen from glucose is GYS2, which is expressed in the liver, while that of the enzyme expressed in muscles is GYS1.

The resulting diseases are known as GSD type 0a (liver cells) and type 0b (muscle cells), which are characterised by low glycogen deposits, thereby affecting energy production.

Another vital enzyme is the branching enzyme, which is encoded by the GBE1 gene and adds glycogen branches. The resulting disease is GSD type IV, brought on by deposits of abnormal glycogen (polyglucosan bodies).

• Deficiencies in  Glycogen Breakdown

Most types of GSD are caused by glycogenolysis, the mechanism by which glycogen is metabolised into glucose. Mutations in the gene for muscle glycogen phosphorylase (PYGM), encoded by PYGM, underlie GSD type V, while mutations in liver phosphorylase (PYGL), encoded by PYGL, result in GSD type VI.

The metabolism of glucose from glucose-6-phosphate in the liver is dependent on glucose-6-phosphatase (G6PC); a deficiency in this gene results in GSD type Ia, known as von Gierke disease.

In GSD type Ib, a deficiency of glucose-6-phosphate transport into the endoplasmic reticulum, encoded by SLC37A4, leads to the accumulation of glycogen because of the inability to release glucose.

• Other Enzyme Defects

In some cases, GSDs develop because of problems with the removal of glycogen branch points. This is because the glycogen-debranching enzyme, encoded by the AGL gene, is involved in the process. Deletions in the AGL gene cause GSD type III, which depends on whether the gene is inactive or partially active.

The uniqueness of GSD type II is that it is a lysosomal storage disorder, in addition to being a glycogen storage disorder. The genetic cause is mutations in the GAA gene, which encodes lysosomal acid α-glucosidase.

• Inheritance Patterns

Most glycogen storage conditions are inherited in an autosomal recessive manner. This is because a child has to receive the gene from both parents to develop the condition. The parents may not have been ill; therefore, they might not know that they are carriers.

On the other hand, some types, like GSD type IX, are X-linked. In X-linked disorders, male carriers of the genetic mutation develop the disorder because they have only one X chromosome.

Taken together, these genetic abnormalities contribute to the variability in disease onset, severity, and presentation in GSDs because different enzymes are targeted.

What are the Symptoms of Glycogen Storage Diseases? 

Symptoms of glycogen storage disease typically occur during infancy or childhood, although these vary depending on the type, with hypoglycemia and exercise intolerance being the most common presentations.

The two most frequent symptoms common to most GSDs are hypoglycemia, which means low blood sugar, and exercise intolerance. Hypoglycemia is caused by the body’s inability to release glucose from storage.

This means that when the body experiences hypoglycemia, the brain and muscles do not receive sufficient energy. Possible symptoms of low blood sugar may include:

• Shaking or Trembling
• Sweating and chills
• “Dizziness” is most
• Weakness & Fatigue
• An increased heart rate
• Severe hunger (Hyperphagia)
• Difficulty thinking or concentrating
• Irritability or Anxiousness
• Easy bruising
• Seizures in Severe Cases

Exercise intolerance is also common, particularly in cases involving muscles. The reason is that the muscles cannot readily derive energy from storage. Thus, exercise may result in weakness, soreness, or spasms even when the exercise is mild.

• Other manifestations of glycogen storage disease may include:
• Muscle weakness/muscle tone that is low
• Muscle spasms and aches
• Delayed growth and failure to gain weight in children
• Enlargement of the liver (hepatomegaly), sometimes resulting in a distended abdomen
• Easy bruising
• Chronic hunger
• High cholesterol (hyperlipidemia)

In a child, persistent low blood sugar and limited energy availability might affect growth. This is because growth might be slowed because the body has been unable to manage glucose effectively, hence, weight gain might be insufficient.

How are Glycogen Storage Diseases Diagnosed?

Glycogen storage disease diagnoses are made using a variety of tests, including blood and urine tests, imaging studies, and genetic tests for abnormalities in glucose metabolism, the liver, muscles, specific enzymes, and genes.

This table gives a detailed overview of how GSDs are diagnosed:

Test	What it shows
Fasting Blood Sugar Test	Low fasting blood glucose suggests GSD because the body can’t properly release stored glucose.
Ketone Blood Test	Elevated ketones indicate the body is using fat for energy instead of glucose, which is common in GSD.
Basic Metabolic Panel	Provides an overview of metabolic health and helps rule out other conditions.
Lipid Panel	Detects high cholesterol levels (hyperlipidemia), which are common in several types of GSD.
Liver Function Tests	Abnormal results may indicate liver involvement, a key feature of many GSDs.
Urinalysis	Measures kidney function and uric acid levels; GSD often causes hyperuricemia.
Abdominal Ultrasound	Checks for an enlarged liver (hepatomegaly).
Genetic Testing	Identifies gene mutations affecting glycogen-related enzymes and helps confirm the GSD type.
Muscle or Liver Biopsy	Performed when genetic testing isn’t conclusive to confirm glycogen accumulation and enzyme defects.

What are the Treatment and Management Options for Glycogen Storage Diseases?

Glycogen storage diseases are managed through a lifelong diet, medications, and treatment plans to keep blood sugar levels stable, with conditions such as enzyme replacement therapy or a liver transplant used in particular cases.

There is no treatment available for glycogen storage disease (GSD), so management is symptomatic. It depends on the type of GSD and which organs are affected. Management aims to maintain stable blood sugar levels, minimise the accumulation of abnormal metabolites, and preserve the involved organs.

• Prevention and Management of Hypoglycemia

The control of hypoglycemia is a fundamental part of the treatment of GSD. Most patients require a daily diet of unsweetened cornstarch. Cornstarch is a complex carbohydrate that is slowly digested, ensuring that glucose is released gradually into the bloodstream. 

Newer preparations of longer-acting agents are also available, so patients may not need to be fed at night. In most cases, when hypoglycemia manifests, it has to be treated immediately by consuming high-carb foods.

In cases where this condition is left untreated, it has a high tendency to result in severe conditions such as the onset of a seizure or coma.

• Handling Metabolic Complications

Some instances of GSD are linked with metabolic abnormalities, which require attention as well. High cholesterol is typically treated with statin medications. High uric acid levels can be managed with allopurinol, which decreases uric acid production.

• Enzyme Replacement Therapy

In some types of GSD, treatment is more direct. For instance, type II GSD can be treated with enzyme replacement therapy (ERT).

The treatment consists of frequent intravenous injections to compensate for the deficient enzyme, resulting in a buildup of glycogen in the body. Researchers are working on a way to extend the treatment to other types of GSD.

• Advanced and Surgical Options

In more serious cases, particularly when there is progressive liver damage, liver transplantation has been suggested. Although it doesn’t affect the genetic problem, it has been shown to result in marked improvement in metabolism in certain patients.

In summary, the management of GSD is a long-term personalised approach. The reason is that, in the case of GSD, the condition cannot be managed on its own, unlike in healthy patients.

FAQs about Glycogen Storage Diseases

1. What is the prognosis of glycogen storage disease?

Early diagnosis and proper care promise a bright future for most people with GSD. But in some cases, GSD is hard to cope with.

2. How is glycogen storage disease diagnosed in a child?

The diagnosis involves reviewing symptoms, conducting a physical exam, and obtaining blood work. In some cases, genetic screening, as well as a liver or muscle biopsy, might be necessary.

3. What are the complications of glycogen storage disorder? 

Complications that can arise are serious cases of hypoglycemia, growth delays, liver problems, heart problems, muscle damage, and/or renal difficulties, depending on the type of GSD.

4. How can glycogen storage disease be prevented?

GSD is not preventable because it is inherited. Early treatment can, though, keep the symptoms at bay.

5. What is the life span of a person with glycogen storage disease?

The lifespan depends on the type, age of onset, and the quality of treatment management. In some types, the conditions are serious, but in others, a close-to-normal lifespan is possible.

Conclusion

Glycogen storage disease is a broad category of genetic disorders that vary significantly from one type to another. Although a cure is not available, a lot can still be done to make life better with proper management. In fact, diet, treatment, enzyme replacement, and support for patients with GSD have improved significantly, necessitating care.

For pursuing NEET PG, DocTutorials can be a valuable companion for studying metabolic disorders, among other high-yield topics. We offer crisp videos, Qbank, exam-focused notes, flashcards, mindmaps, and much more to ensure aspirants gain complete clarity over complex NEET PG concepts.

Join DocTutorials today and explore our NEET PG course to excel in your medical career!